JP2020522249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522249A5 JP2020522249A5 JP2019565890A JP2019565890A JP2020522249A5 JP 2020522249 A5 JP2020522249 A5 JP 2020522249A5 JP 2019565890 A JP2019565890 A JP 2019565890A JP 2019565890 A JP2019565890 A JP 2019565890A JP 2020522249 A5 JP2020522249 A5 JP 2020522249A5
- Authority
- JP
- Japan
- Prior art keywords
- hpiv3
- amino acid
- acid sequence
- rsv
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712003 Human respirovirus 3 Species 0.000 claims description 76
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 108091006027 G proteins Proteins 0.000 claims description 21
- 102000030782 GTP binding Human genes 0.000 claims description 21
- 108091000058 GTP-Binding Proteins 0.000 claims description 21
- 210000005220 cytoplasmic tail Anatomy 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 12
- 241000726041 Human respirovirus 1 Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 101150008820 HN gene Proteins 0.000 claims description 6
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 101150034814 F gene Proteins 0.000 claims description 4
- 101150062031 L gene Proteins 0.000 claims description 4
- 101150084044 P gene Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 2
- 241000712005 Bovine respirovirus 3 Species 0.000 claims description 2
- 101710117545 C protein Proteins 0.000 claims description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 2
- 101900208483 Human parainfluenza 3 virus Fusion glycoprotein F0 Proteins 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 101710085938 Matrix protein Proteins 0.000 claims description 2
- 101710127721 Membrane protein Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 101710141454 Nucleoprotein Proteins 0.000 claims description 2
- 102100034574 P protein Human genes 0.000 claims description 2
- 108010015724 Prephenate Dehydratase Proteins 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023063846A JP2023093566A (ja) | 2017-05-29 | 2023-04-11 | Ｒｓｖ ｇを発現する組換えキメラウシ／ヒトパラインフルエンザウイルス３およびその使用法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512111P | 2017-05-29 | 2017-05-29 | |
| US62/512,111 | 2017-05-29 | ||
| PCT/US2018/034848 WO2018222573A1 (en) | 2017-05-29 | 2018-05-29 | Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023063846A Division JP2023093566A (ja) | 2017-05-29 | 2023-04-11 | Ｒｓｖ ｇを発現する組換えキメラウシ／ヒトパラインフルエンザウイルス３およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522249A JP2020522249A (ja) | 2020-07-30 |
| JP2020522249A5 true JP2020522249A5 (enExample) | 2021-05-27 |
| JP7314059B2 JP7314059B2 (ja) | 2023-07-25 |
Family
ID=62685166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565890A Active JP7314059B2 (ja) | 2017-05-29 | 2018-05-29 | Ｒｓｖ ｇを発現する組換えキメラウシ／ヒトパラインフルエンザウイルス３およびその使用法 |
| JP2023063846A Pending JP2023093566A (ja) | 2017-05-29 | 2023-04-11 | Ｒｓｖ ｇを発現する組換えキメラウシ／ヒトパラインフルエンザウイルス３およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023063846A Pending JP2023093566A (ja) | 2017-05-29 | 2023-04-11 | Ｒｓｖ ｇを発現する組換えキメラウシ／ヒトパラインフルエンザウイルス３およびその使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11273214B2 (enExample) |
| EP (1) | EP3630173A1 (enExample) |
| JP (2) | JP7314059B2 (enExample) |
| CN (1) | CN110996998A (enExample) |
| CA (1) | CA3064267A1 (enExample) |
| WO (1) | WO2018222573A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4329797A1 (en) * | 2021-04-27 | 2024-03-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant chimeric bovine/human parainfluenza virus 3 expressing sars-cov-2 spike protein and its use |
| MX2024006506A (es) | 2021-11-30 | 2024-08-14 | Sanofi Pasteur Inc | Vacunas basadas en vectores virales de metapneumovirus humano. |
| CN115925822B (zh) * | 2022-09-01 | 2024-01-09 | 广州源博医药科技有限公司 | 一种重组蛋白及其在制备呼吸道合胞病毒疫苗中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU605476B2 (en) * | 1986-01-14 | 1991-01-17 | University Of North Carolina, The | Vaccines for human respiratory virus |
| US7201907B1 (en) | 1997-05-23 | 2007-04-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines |
| US7632508B2 (en) | 1997-05-23 | 2009-12-15 | The United States Of America | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| US7250171B1 (en) | 1997-05-23 | 2007-07-31 | United States Of America As Represented By The Dept. Of Health & Human Services | Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein |
| WO1998053078A1 (en) | 1997-05-23 | 1998-11-26 | The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
| US7192593B2 (en) | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| US20030082209A1 (en) | 2000-07-05 | 2003-05-01 | Skiadopoulos Mario H. | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| US7208161B1 (en) | 1997-05-23 | 2007-04-24 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
| JP4795597B2 (ja) * | 1999-12-10 | 2011-10-19 | アメリカ合衆国 | パラインフルエンザウィルス（ｐｉｖ）及びヒトの病原体により引き起こされる感染及び疾病を保護するためへの組換えｐｉｖのベクターとしての使用 |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| TWI344991B (en) | 2002-02-21 | 2011-07-11 | Medimmune Vaccines Inc | Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences |
| CA2477037C (en) * | 2002-02-21 | 2014-12-09 | Mount Sinai School Of Medicine | Recombinant negative strand virus rna expression systems and vaccines |
| US20050142148A1 (en) | 2003-04-25 | 2005-06-30 | Fouchier Ronaldus A.M. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| US9216212B2 (en) * | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US20090017517A1 (en) | 2007-07-13 | 2009-01-15 | Medimmune, Llc | Preparation of Negative-Stranded RNA Viruses by Electroporation |
| JP7020917B2 (ja) | 2015-01-20 | 2022-02-16 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | キメラｒｓｖ／ｂｐｉｖ３ ｆタンパクを発現する組換えヒト／ウシパラインフルエンザウイルス３（ｂ／ｈｐｉｖ３）およびその使用 |
| KR102854980B1 (ko) * | 2015-12-11 | 2025-09-03 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주 |
-
2018
- 2018-05-29 WO PCT/US2018/034848 patent/WO2018222573A1/en not_active Ceased
- 2018-05-29 US US16/616,873 patent/US11273214B2/en active Active
- 2018-05-29 CN CN201880048358.8A patent/CN110996998A/zh active Pending
- 2018-05-29 EP EP18733056.8A patent/EP3630173A1/en active Pending
- 2018-05-29 CA CA3064267A patent/CA3064267A1/en active Pending
- 2018-05-29 JP JP2019565890A patent/JP7314059B2/ja active Active
-
2022
- 2022-02-01 US US17/590,631 patent/US11975063B2/en active Active
-
2023
- 2023-04-11 JP JP2023063846A patent/JP2023093566A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagai | Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding | |
| Luongo et al. | Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature | |
| Buchholz et al. | Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter | |
| US5716821A (en) | Prevention and treatment of respiratory tract disease | |
| Baron et al. | Rescue of rinderpest virus from cloned cDNA | |
| Biacchesi et al. | Recombinant human metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate | |
| Clarke et al. | Rescue of mumps virus from cDNA | |
| Liang et al. | Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate | |
| Peeters et al. | Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence | |
| Durbin et al. | Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates | |
| Collins et al. | New generation live vaccines against human respiratory syncytial virus designed by reverse genetics | |
| Garcin et al. | A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture | |
| Nagai et al. | Paramyxovirus reverse genetics is coming of age | |
| Skiadopoulos et al. | Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp 45) human parainfluenza virus 3 candidate vaccine | |
| WO2012089231A1 (en) | Paramyxovirus vaccines | |
| CN100491531C (zh) | 通过缺失或消除非必需基因而减毒的重组副流感病毒疫苗 | |
| AU2009202359A1 (en) | Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens | |
| JP4549188B2 (ja) | 組換えヒト２型パラインフルエンザウイルス（ＨＰＩＶ２）のｃＤＮＡからの回収（ｒｅｃｏｖｅｒｙ）、並びにＰＩＶおよび他のヒト病原体に対する免疫応答を誘発する免疫原性組成物における、そしてベクターとしての組換えＨＰＩＶ２の使用 | |
| EP4190895A1 (en) | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization | |
| JP2003516148A (ja) | パラインフルエンザウィルス（ｐｉｖ）及びヒトの病原体により引き起こされる感染及び疾病を保護するためへの組換えｐｉｖのベクターとしての使用 | |
| Skiadopoulos et al. | Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins | |
| Newman et al. | Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics | |
| Nagai et al. | Accessory genes of the paramyxoviridae, a large family of nonsegmented negative-strand RNA viruses, as a focus of active investigation by reverse genetics | |
| CN101392239A (zh) | 减毒的人-牛嵌合副流感病毒(piv)疫苗 | |
| Bailly et al. | A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates |